Figures & data
Table 1 HER2 breast cancer cell-line panel
Figure 1 Heat map of maximum cell-growth inhibition induced by the individual compounds in the various cell lines.
![Figure 1 Heat map of maximum cell-growth inhibition induced by the individual compounds in the various cell lines.](/cms/asset/f87ed05e-f2f9-4e98-bc6b-5ec079859784/dbct_a_28356768_f0001_c.jpg)
Figure 2 Cell lines divided into three groups based on response to trastuzumab and lapatinib.
![Figure 2 Cell lines divided into three groups based on response to trastuzumab and lapatinib.](/cms/asset/d7b8ea8d-c4ba-4a3c-86c0-0f67d5617176/dbct_a_28356768_f0002_c.jpg)
Figure 3 Box plots showing trastuzumab and lapatinib response in 13 HER2 positive cell lines relative to PIK3CA and PTEN status.
![Figure 3 Box plots showing trastuzumab and lapatinib response in 13 HER2 positive cell lines relative to PIK3CA and PTEN status.](/cms/asset/c0ae2a79-6bcb-424a-a2ba-52f5ab41ddd1/dbct_a_28356768_f0003_c.jpg)
Figure 4 Akt1/2 kinase-inhibitor response.
![Figure 4 Akt1/2 kinase-inhibitor response.](/cms/asset/d1371684-632b-4dd7-a1de-da525550ffa4/dbct_a_28356768_f0004_c.jpg)
Figure 5 The five drug–gene associations found by both Spearman’s correlation and through elastic-net analysis for the Akt1/2 kinase inhibitor.
![Figure 5 The five drug–gene associations found by both Spearman’s correlation and through elastic-net analysis for the Akt1/2 kinase inhibitor.](/cms/asset/fbe067a4-f3cb-4f9a-ade0-5adc64217e48/dbct_a_28356768_f0005_c.jpg)